Glycoengineering of Natural Killer Cells with CD22 Ligands for Enhanced Anticancer Immunotherapy
Xianwu Wang, Shuyao Lang, Yunpeng Tian, Jianghong Zhang, Xu Yan, Zhihong Fang, Jian Weng, Na Lü, Xuanjun Wu, Tianlu Li, Hongzhi Cao, Li Zhu, Xuefei Huang
Abstract
lymphoma cell lines and primary lymphoma cells from human cancer patients can be effectively killed by the engineered NK cells. Furthermore, glycoengineered NK cells provided significant protection to tumor-bearing mice. Thus, NK cell glycoengineering is an exciting new approach for cancer treatment complementing the current immune cell genetic engineering strategy.
Topics & Concepts
Immune systemImmunotherapyCancer cellCancer researchCD22LymphomaCytotoxic T cellCancer immunotherapyNKG2DNatural killer cellCancerBiologyImmunologyChemistryBiochemistryIn vitroGeneticsCD19Immune Cell Function and InteractionCAR-T cell therapy researchT-cell and B-cell Immunology